Bendectin and fetal development. A study of Boston City Hospital.
As part of a prospective study investigating maternal characteristics and habits during pregnancy and their impact on fetal development, 1,690 mother/infant pairs were studied. Of the mothers, 375 reported using Bendectin during pregnancy. Multivariate analyses examining birth weight, length, head circumference, gestational age, and congenital malformations as dependent variables demonstrated no associations between Bendectin exposure and adverse fetal outcome.
D000014:Abnormalities, Drug-Induced; D000932:Antiemetics / Q000009:adverse effects*; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects*; D004025:Dicyclomine / Q000009:adverse effects*; D004319:Doxylamine / Q000009:adverse effects*; D004338:Drug Combinations / Q000009:adverse effects; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007407:Interviews as Topic; D011247:Pregnancy; D011295:Prenatal Care; D011446:Prospective Studies; D011725:Pyridines / Q000009:adverse effects*; D011736:Pyridoxine / Q000009:adverse effects*; D012306:Risk; D013723:Teratogens
D000932:Antiemetics; D003509:Cyclohexanecarboxylic Acids; D004338:Drug Combinations; D011725:Pyridines; D013723:Teratogens; C004454:dicyclomine, doxylamine, pyridoxine drug combination; D004025:Dicyclomine; D004319:Doxylamine; D011736:Pyridoxine